Physician profile
Julia E Lansing
NPI 1518150911
$2,930.84
in general payments reported to CMS, 2019-2025
20 companies · $1,316 in 2025
The $1,316 reported for 2025 was more than what 90% of Psychiatric/Mental Health, Adult (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.44 · 2022: $185 · 2023: $696 · 2024: $705 · 2025: $1,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,716.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $560.84 | 2022-2025 | Ingrezza |
| Alkermes, INC. | $457.15 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $417.72 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $234.96 | 2023-2025 | Uzedy, Austedo Xr, Austedo |
| Axsome Therapeutics, INC. | $226.48 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $206.33 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $192.58 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $177.75 | 2022-2025 | Invega Sustenna, Invega Trinza, Invega |
| E.R. Squibb & Sons, L.L.C. | $139.21 | 2025 | Cobenfy |
| Lundbeck LLC | $76.19 | 2023-2025 | Rexulti |
| Almatica Pharma LLC | $57.68 | 2023-2025 | Loreev Xr, Gralise |
| Sunovion Pharmaceuticals INC. | $41.32 | 2022 | |
| Vanda Pharmaceuticals INC. | $32.89 | 2025 | Fanapt |
| Merck Sharp & Dohme LLC | $20.25 | 2023 | Belsomra |
| Corium, LLC | $19.54 | 2023 | Azstarys |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $18.33 | 2025 | Brixadi |
| Indivior INC. | $16.78 | 2023 | Perseris |
| Luye Pharma (USA) Ltd. | $15.46 | 2025 | Erzofri Extended-Release |
| Biogen, INC. | $14.71 | 2024 | |
| Janssen Biotech, INC. | $4.67 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Lansing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.